Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 4/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.40 |
| ▸ | PTPRB | P23467 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | KDM4A | O75164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PPID | Q08752 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2841433 | 0.85 | GABRP (0.46) | GLSL3MBTL1SREBF2BRD4NAMPT | |
| SCHEMBL21455931 | 0.85 | L3MBTL1 (0.45) | GLSL3MBTL1SREBF2BRD4NAMPT | |
| SCHEMBL26141744 | 0.82 | L3MBTL1 (0.45) | GLSL3MBTL1SREBF2BRD4NAMPT | |
| SCHEMBL509487 | 0.82 | KDM5B (0.53) | BRD4NAMPTLMNAMAPTCA12 | |
| SCHEMBL190869 | 0.82 | IGF1R (0.44) | L3MBTL1SMN1; SMN2NPC1PKMRAB9A | |
| SCHEMBL29085960 | 0.81 | L3MBTL1 (0.44) | GLSL3MBTL1SREBF2BRD4NAMPT | |
| SCHEMBL8786889 | 0.81 | MAPT (0.51) | L3MBTL1NAMPTSMN1; SMN2LMNAMAPT | |
| SCHEMBL16020311 | 0.81 | KDM4A (0.44) | L3MBTL1SREBF2BRD4NAMPTKDM4A | |
| SCHEMBL14228526 | 0.80 | BRD4 (0.48) | GLSL3MBTL1BRD4NAMPTKDM4A | |
| SCHEMBL23705856 | 0.78 | GLS (0.47) | GLSBRD4NAMPTKDM4ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010130708-A9 | BETA-LACTAMASE INHIBITORS | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2011-01-13 | — | — | WO | disclosed |
| WO-2010130708-A1 | BETA-LACTAMASE INHIBITORS | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2010-11-18 | — | — | WO | disclosed |
| US-20100292185-A1 | BETA-LACTAMASE INHIBITORS | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD (BM) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292185-A1 | BETA-LACTAMASE INHIBITORS | GANAB, BPGM, BLVRB | GLS 422/4885L3MBTL1 1425/4885SREBF2 3487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.